MAPT and Alzheimer disease: Therefore, an ideal AD drug may target multiple facets of the disease including inflammatory and metabolic components occurring early in disease, along with reducing pathogenic amyloid beta, hyperphosphorylated tau, and synaptic dysfunction later in the disease.